Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in BFLY.
← Back to Free Index

BFLY

Analysis as of: 2026-08-28
Butterfly Network, Inc.
Butterfly Network sells handheld ultrasound devices, cloud workflow software, and embedded Ultrasound-on-Chip licensing for healthcare and adjacent partners.
ai enterprise healthcare medical devices software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Portable imaging with platform upside, valuation discipline required
The business has moved beyond a single handheld probe story, but the market already prices in meaningful success. The realistic upside is strong if workflow, compliance, and Embedded monetization become repeatable, not merely promotional.

Analysis

Thesis
Butterfly can plausibly create a 2x+ equity outcome by 2031 if it converts a differentiated handheld ultrasound franchise into a higher-quality mix of enterprise workflow, regulated trust software, and repeatable embedded licensing; AI expands scan volume, but the real upside comes from owning the verified clinical workflow around the scan.
Last Economy Alignment
AI should make ultrasound acquisition, guidance, and review useful to many more clinicians, expanding demand for Butterfly’s probe and workflow stack. The score stops short of very high because bigger imaging vendors and device-agnostic AI could still capture much of the software value.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.1x (from 5 most recent analyses)
Reasoning
The upside comes from mix shift more than heroic unit assumptions. Butterfly already has a real product, growing software, and early Embedded proof, so 5-year revenue can scale meaningfully; however, hardware exposure, regulated selling cycles, and milestone lumpiness argue for multiple compression from today rather than a pure software rerating.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The biggest risk is not product viability; it is revenue quality. Butterfly must prove that software, regulated workflow, and Embedded become repeatable and durable before larger vendors, procurement friction, or valuation gravity pull the story back toward premium-device status.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.35
AI should make ultrasound useful to far more clinicians, and this company controls the probe plus part of the cloud workflow around each scan. The risk is that bigger vendors or generic AI tools capture the software layer while Butterfly remains mostly a premium hardware seller.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$9.31
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case